Merck scraps another late-stage Alzheimer's drug study

NEW YORK (Reuters) - Merck&Co Inc on Tuesday said it will end another late-stage trial of an Alzheimer's drug because it was unlikely to work, adding to the pile-up of failures to find an effective treatment for the mind-wasting disease.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Diet tested on mice proves more beneficial in some cases than restricting caloriesA new study that found a low-protein, high-carbohydrate diet led to improved brain health in mice has sparked hopes carbohydrates could help ward off dementia.Researchers at Sydney University ’s Charles Perkins Centre fed the mice complex carbohydrates derived from starch, and casein protein, which is found in cheese and milk.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Dementia Diets and dieting Health Alzheimer's Sydney Medical research Australia news Source Type: news
When I finished my training, I was taught that the vast majority of dementia was Alzheimer’s disease, with occasional cases of multi-infarct dementia as well as odd syndromes such as Kreutzfeld-Jacob disease and genetic, traumatic, toxic and tumor-related syndromes. Parkinson’s disease, we were taught, caused a tremor and freezing up of a person’s movements and […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions Geriatrics Neurology Source Type: blogs
Adherence to the Mediterranean diet is significantly associated with a reduction over time in beta-amyloid accumulation, a biomarker of cerebral Alzheimer's disease pathology, new research suggests.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Source Type: news
Soft Matter, 2018, Advance Article DOI: 10.1039/C8SM01636D, PaperGalya Staneva, Nicolas Puff, Stanislav Stanimirov, Todor Tochev, Miglena I. Angelova, Michel Seigneuret The Alzheimer amyloid β-peptide binds to the liquid-disordered lipid phase and modulates the nanodomain–microdomain size dynamics of raft-mimicking Lo domains in model membranes containing the ganglioside GM1. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Soft Matter latest articles - Category: Chemistry Authors: Source Type: research
The first is the treatment in a clinical trial of the first patient that uses focused ultrasound to open the blood brain barrier.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
The small study of 61 patients at Washington University suggests a technique that, if successful, would be a better alternative to the current questionnaire screening method.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Condition:   Alzheimer Dementia Intervention:   Drug: Allopregnanolone Sponsors:   University of Southern California;   University of Arizona;   Alzheimer's Association Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(Natural News) A new therapy based on ultrasound waves might be able to improve the cognitive powers of patients suffering from Alzheimer’s disease and other forms of dementia. According to an article on the Tohoku University news page, the approach improved the condition of mice with symptoms similar to human dementia. In their experiment, the...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
University of Texas, Southwestern, scientists have developed a new vaccine that supercharged mice's own immune systems to fight Alzheimer's proteins without side effects.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
A DNA vaccine tested in mice that cuts the accumulation of both types of toxic proteins associated with Alzheimer's disease could halve cases of dementia, scientists believe. Scientists say that the new findings may pave the way to a clinical trial for a potential dementia jab.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
More News: Alzheimer's | Health | Merck | Study